FAB-144: Difference between revisions
CSV import |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 28: | Line 28: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:FAB-144 structure.png|FAB-144 | |||
</gallery> | |||
Latest revision as of 21:02, 16 March 2025
FAB-144 is a type of synthetic cannabinoid, which is a group of chemical compounds that mimic the effects of cannabinoids naturally produced by the cannabis plant. FAB-144 was first identified in Japan in 2013, and it is sold as a designer drug.
Chemistry[edit]
FAB-144 is a derivative of indazole, a type of organic compound. It is specifically an indazole-3-carboxamide, which means it has a carboxamide group attached to the third carbon atom of the indazole ring. The full chemical name of FAB-144 is N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide.
Effects[edit]
The effects of FAB-144 are similar to those of other synthetic cannabinoids and can include euphoria, relaxation, and altered perception. However, because it is a research chemical, the full range of its effects is not well understood. It is known to be a potent agonist of the CB1 receptor, which is found in the brain and is responsible for the psychoactive effects of cannabis.
Legal status[edit]
FAB-144 is illegal in many countries, including the United States, where it is classified as a Schedule I drug under the Controlled Substances Act. It is also banned in many European countries under the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Health risks[edit]
As with other synthetic cannabinoids, FAB-144 can have serious health risks. These can include psychosis, seizures, and even death. Because it is often sold as a legal alternative to cannabis, users may not be aware of these risks.
